Neoplasms

Blood and Lymph Conditions

All Conditions

Infections

Symptoms and General Pathology

Rare Diseases

Leukemia

Leukemia, Myeloid

Leukemia, Myeloid, Acute

Aspergillosis

Neoplasms by Histologic Type

Hematologic Diseases

Mycoses

Communicable Diseases

Bacterial Infections

Bacterial Infections and Mycoses

Myeloid Leukemia

Acute Myeloid Leukemia

Acute Non Lymphoblastic Leukemia

Acute Graft Versus Host Disease

Anti-Infective Agents

All Drugs and Chemicals

Clotrimazole

Miconazole

Antifungal Agents

Posaconazole

Anti-Infective Agents, Local

Enzyme Inhibitors

Cytochrome P-450 Enzyme Inhibitors

Hormones

Hormone Antagonists

Cytochrome P-450 CYP3A Inhibitors

Patients with acute myeloid leukemia treated with intensive chemotherapy. From 2009 to 2011, any patient received antifungal (anti-aspergillosis) prophylaxis.

Patients with acute myeloid leukemia treated with intensive chemotherapy. From 2012 to 2015, all patients received antifungal (anti-aspergillosis) prophylaxis by posaconazole.

Epidemiology data: clinical and biological informations collecting

Patients without antifungal prophylaxis

Hospitalized patients between 2012 and 2015 received Posaconazole prophylaxis during neutropenia period induced by induction or salvage chemotherapy.

Patients with antifungal prophylaxis

Gaelle Guillerm, MD

Lenaig Le Clech, MD

Patients with acute myeloid leukemia (AML) are at risk to develop severe infections whose invasive aspergillosis (IA). These infections are leading to an important morbidity and mortality. Antifungal prophylaxis is recommended by posaconazole for AML patients during neutropenia induced by induction chemotherapy. Their application is not uniform.

Invasive aspergillosis are frequent infections in hematological malignancy in particular during neutropenia induced by chemotherapy. Their incidence ranged between 5 to 25% according to the literature. Mortality may reach 30%. Our study described IA incidence in AML patients treated by intensive chemotherapy depending on antifungal prophylaxis by posaconazole. From 2009 to 2011, any patients received antifungal prophylaxis. From 2012 to 2015, patients received posaconazole during induction and salvage chemotherapy. During the all study period, efficacy of posaconazole is evaluated according to construction/demolition periods in hospital. All patients are hospitalized in High Efficiency Particulate Air (HEPA) filtration system.

Invasives Aspergillosis in Acute Myeloid Leukemia

The Incidence of Invasive Aspergillosis in Acute Myeloid Leukemia

Evaluation of annual incidence of invasive aspergillosis in acute myeloid leukemia treated by intensive chemotherapy between 2009 and 2015

Comparison of two periods: 2009-2011 where patients had not antifungal prophylaxis and 2012-2015 where patients had antifungal prophylaxis by posaconazole during induction and salvage chemotherapy

Comparison of incidence of invasive aspergillosis while antifungal prophylaxis and construction/demolition periods

University Hospital, Brest

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Invasives Aspergillosis in Acute Myeloid Leukemia	NCT02900430	Acute Myeloid L... Invasive Asperg...	Patients withou... Patients with a...	18 Years -	University Hospital, Brest
Invasives Aspergillosis in Acute Myeloid Leukemia	NCT02900430	Acute Myeloid L... Invasive Asperg...	Patients withou... Patients with a...	18 Years -	University Hospital, Brest
Invasives Aspergillosis in Acute Myeloid Leukemia	NCT02900430	Acute Myeloid L... Invasive Asperg...	Patients withou... Patients with a...	18 Years -	University Hospital, Brest

Spots Global Cancer Trial Database for patients without antifungal prophylaxis